Gert van der Hoek
In Memoriam - Editor, Senior Moderator
Ertapenem resistance still very low.
ESBL in 11% of E-Coli isolates in Europe
Susceptibility of European Escherichia coli Clinical Isolates from Intra-Abdominal Infections, ESBL-Occurrence, Resistance Distribution, and Molecular Characterization of Ertapenem Resistant Isolates (SMART 2008-2009)
Abstract
A total of 3,160 clinical isolates of Escherichia coli from intra-abdominal infections were collected during 2008 ? 2009 from 13 European countries. The rate of extended-spectrum beta-lactamase (ESBL) producing isolates in Europe was 11%.
The most active antibiotics tested were typically imipenem, ertapenem, and amikacin, though the activity of all non-carbapenem antibiotics was lower when tested against ESBL-positive isolates as compared with ESBL-negative isolates. Ertapenem exhibited 99.4% susceptibility with all isolates, and 96.8% with ESBL-positive isolates.
Applying the ertapenem CLSI clinical breakpoint for resistance (MIC ≥1 μg/ml), only 5 isolates (0.2%) were ertapenem-resistant, of which only three were available for molecular characterization. Of those three, only one was ESBL-positive (CTX-M-14), and two were carbapenemase-positive (OXA-48). All three were negative for, VIM, NDM and KPC carbapenemases.
Although ertapenem-resistance in E. coli is very low, further monitoring of ertapenem susceptibility and molecular characterization of ertapenem-resistant isolates is needed.
Clinical Microbiology and Infection
ESBL in 11% of E-Coli isolates in Europe
Susceptibility of European Escherichia coli Clinical Isolates from Intra-Abdominal Infections, ESBL-Occurrence, Resistance Distribution, and Molecular Characterization of Ertapenem Resistant Isolates (SMART 2008-2009)
Abstract
A total of 3,160 clinical isolates of Escherichia coli from intra-abdominal infections were collected during 2008 ? 2009 from 13 European countries. The rate of extended-spectrum beta-lactamase (ESBL) producing isolates in Europe was 11%.
The most active antibiotics tested were typically imipenem, ertapenem, and amikacin, though the activity of all non-carbapenem antibiotics was lower when tested against ESBL-positive isolates as compared with ESBL-negative isolates. Ertapenem exhibited 99.4% susceptibility with all isolates, and 96.8% with ESBL-positive isolates.
Applying the ertapenem CLSI clinical breakpoint for resistance (MIC ≥1 μg/ml), only 5 isolates (0.2%) were ertapenem-resistant, of which only three were available for molecular characterization. Of those three, only one was ESBL-positive (CTX-M-14), and two were carbapenemase-positive (OXA-48). All three were negative for, VIM, NDM and KPC carbapenemases.
Although ertapenem-resistance in E. coli is very low, further monitoring of ertapenem susceptibility and molecular characterization of ertapenem-resistant isolates is needed.
Clinical Microbiology and Infection